CTKB (STOCKS)
Cytek Biosciences, Inc. Common Stock
$4.590000
+0.060000 (+1.32%)
Prev close: $4.530000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Medical Specialties
- CEO
- Wen Bin Jiang
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $589.40M
- Employees
- 688
- P/E (TTM)
- -8.83
- P/B (TTM)
- 1.70
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
4
Buy
4
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.04 | $-0.02 | -0.0196 | -96.08% |
|
Sep 2025 (Q3)
|
$-0.04 | $-0.05 | +0.0136 | +25.37% |
|
Jun 2025 (Q2)
|
$-0.04 | $-0.07 | +0.0314 | +43.98% |
|
Mar 2025 (Q1)
|
$-0.09 | $-0.05 | -0.0441 | -96.08% |
Financial Statements
| Revenues | $201.49M |
| Benefits Costs and Expenses | $231.33M |
| Cost Of Revenue | $97.03M |
| Costs And Expenses | $231.33M |
| Gross Profit | $104.46M |
| Nonoperating Income/Loss | $10.54M |
| Operating Expenses | $144.84M |
| Research and Development | $36.47M |
| Other Operating Expenses | $108.38M |
| Operating Income/Loss | -$40.38M |
| Income/Loss From Continuing Operations After Tax | -$66.54M |
| Income/Loss From Continuing Operations Before Tax | -$29.84M |
| Income Tax Expense/Benefit | $36.70M |
| Income Tax Expense/Benefit, Current | $3.14M |
| Income Tax Expense/Benefit, Deferred | $33.56M |
| Net Income/Loss | -$66.54M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$66.54M |
| Net Income/Loss Available To Common Stockholders, Basic | -$66.54M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Average Shares | 127,745,939 |
| Diluted Average Shares | 127,745,939 |
| Assets | $461.54M |
| Current Assets | $392.00M |
| Inventory | $48.43M |
| Other Current Assets | $343.57M |
| Noncurrent Assets | $69.55M |
| Fixed Assets | $18.01M |
| Intangible Assets | $16.82M |
| Other Non-current Assets | $34.72M |
| Liabilities | $119.80M |
| Current Liabilities | $77.80M |
| Noncurrent Liabilities | $42.00M |
| Equity | $341.74M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $341.74M |
| Liabilities And Equity | $461.54M |
| Net Cash Flow From Operating Activities | -$4.69M |
| Net Cash Flow From Operating Activities, Continuing | -$4.69M |
| Net Cash Flow From Investing Activities | $10.12M |
| Net Cash Flow From Investing Activities, Continuing | $10.12M |
| Net Cash Flow From Financing Activities | -$13.43M |
| Net Cash Flow From Financing Activities, Continuing | -$13.43M |
| Exchange Gains/Losses | $109.00K |
| Net Cash Flow | -$7.89M |
| Net Cash Flow, Continuing | -$8.00M |
| Comprehensive Income/Loss | -$64.31M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$64.31M |
| Other Comprehensive Income/Loss | $2.23M |